Business Wire

Paracrine Announces Publication of STAR Trial, Including Improvement in Hand Function and Quality of Life in Patients With Diffuse Cutaneous Scleroderma

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...
Business Wire

Paracrine Receives FDA Approval to Launch a U.S. Pivotal Trial in Patients With Hand Dysfunction Due to Diffuse Cutaneous Scleroderma

Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...
National Academies of Sciences%2c Engineering%2c and Medicine

Selected Immune Disorders and Disability

Systemic sclerosis (SSc), or scleroderma, is a chronic, multisystem autoimmune rheumatic disease characterized by exaggerated fibrosis, vasculopathy, and derangements of the immune system. When ...
Medscape

Serum Type I Interferon Score May Predict Outcome in Diffuse Cutaneous Systemic Sclerosis

High serum type I interferon (IFN) scores, measured through six chemokines, correlated with poorer lung function and health-related quality of life in patients with diffuse cutaneous systemic ...
Healio

Low-dose steroids fail to improve skin fibrosis in early diffuse systemic sclerosis

Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not. One ...